Angiotensin-converting enzyme-1 gene insertion/deletion polymorphism may be associated with COVID-19 clinical severity: a prospective cohort study.

IF 1.5 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Annals of Saudi Medicine Pub Date : 2021-05-01 Epub Date: 2021-06-01 DOI:10.5144/0256-4947.2021.141

Ozgur Gunal, Ozlem Sezer, Goksenin Unluguzel Ustun, Cagatay Erman Ozturk, Ahmet Sen, Serbulent Yigit, Mehmet Derya Demirag

{"title":"Angiotensin-converting enzyme-1 gene insertion/deletion polymorphism may be associated with COVID-19 clinical severity: a prospective cohort study.","authors":"Ozgur Gunal, Ozlem Sezer, Goksenin Unluguzel Ustun, Cagatay Erman Ozturk, Ahmet Sen, Serbulent Yigit, Mehmet Derya Demirag","doi":"10.5144/0256-4947.2021.141","DOIUrl":null,"url":null,"abstract":"Background: Angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism may play a role in the pathogenesis of coronavirus-19 disease (COVID-19).Objectives: Investigate the relationship between ACE I/D polymorphism and the clinical severity of COVID-19.Design: Prospective cohort study.Setting: Tertiary care hospital.Patients and methods: The study included COVID-19 patients with asymptomatic, mild, and severe disease with clinical data and whole blood samples collected from 1 April 2020 to 1 July 2020. ACE I/D genotypes were determined by polymerase chain reaction and agarose gel electrophoresis.Main outcome measure: ACE DD, DI and II genotypes frequencies.Sample size: 90 cases, 30 in each disease severity group.Results: Age and the frequency of general comorbidity increased significantly from the asymptomatic disease group to the severe disease group. Advanced age, diabetes mellitus and presence of ischemic heart disease were independent risk factors for severe COVID-19 [OR and 95 % CI: 1.052 (1.021-1.083), 5.204 (1.006-26.892) and 5.922 (1.109-31.633), respectively]. The ACE II genotype was the dominant genotype (50%) in asymptomatic patients, while the DD genotype was the dominant genotype (63.3 %) in severe disease. The ACE II geno-type was protective against severe COVID-19 [OR and 95% CI: .323 (.112-.929)]. All nine patients (8.9%) who died had severe disease.Conclusions: The clinical severity of COVID-19 infection may be associated with the ACE I/D polymorphism.Limitations: Small sample size and single center.Conflict of interest: None.","PeriodicalId":8016,"journal":{"name":"Annals of Saudi Medicine","volume":"41 3","pages":"141-146"},"PeriodicalIF":1.5000,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1b/fa/0256-4947.2021.141.PMC8176375.pdf","citationCount":"26","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Saudi Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5144/0256-4947.2021.141","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/6/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 26

Abstract

Background: Angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism may play a role in the pathogenesis of coronavirus-19 disease (COVID-19).

Objectives: Investigate the relationship between ACE I/D polymorphism and the clinical severity of COVID-19.

Design: Prospective cohort study.

Setting: Tertiary care hospital.

Patients and methods: The study included COVID-19 patients with asymptomatic, mild, and severe disease with clinical data and whole blood samples collected from 1 April 2020 to 1 July 2020. ACE I/D genotypes were determined by polymerase chain reaction and agarose gel electrophoresis.

Main outcome measure: ACE DD, DI and II genotypes frequencies.

Sample size: 90 cases, 30 in each disease severity group.

Results: Age and the frequency of general comorbidity increased significantly from the asymptomatic disease group to the severe disease group. Advanced age, diabetes mellitus and presence of ischemic heart disease were independent risk factors for severe COVID-19 [OR and 95 % CI: 1.052 (1.021-1.083), 5.204 (1.006-26.892) and 5.922 (1.109-31.633), respectively]. The ACE II genotype was the dominant genotype (50%) in asymptomatic patients, while the DD genotype was the dominant genotype (63.3 %) in severe disease. The ACE II geno-type was protective against severe COVID-19 [OR and 95% CI: .323 (.112-.929)]. All nine patients (8.9%) who died had severe disease.

Conclusions: The clinical severity of COVID-19 infection may be associated with the ACE I/D polymorphism.

Limitations: Small sample size and single center.

Conflict of interest: None.

查看原文本刊更多论文

血管紧张素转换酶-1基因插入/缺失多态性可能与COVID-19临床严重程度相关:一项前瞻性队列研究

背景:血管紧张素转换酶(ACE)插入/缺失(I/D)多态性可能在冠状病毒-19病(COVID-19)的发病机制中发挥作用。目的:探讨ACE I/D多态性与COVID-19临床严重程度的关系。设计:前瞻性队列研究。环境:三级保健医院。患者和方法:研究纳入2020年4月1日至2020年7月1日采集的无症状、轻度和重度COVID-19患者的临床资料和全血样本。采用聚合酶链反应和琼脂糖凝胶电泳检测ACE I/D基因型。主要结局指标:ACE DD、DI和II基因型频率。样本量:90例，每个疾病严重程度组30例。结果:从无症状组到重症组，年龄和一般合并症的发生频率明显增加。高龄、糖尿病和存在缺血性心脏病是重症COVID-19的独立危险因素[OR和95% CI分别为1.052(1.021-1.083)、5.204(1.006-26.892)和5.922(1.109-31.633)]。无症状患者以ACE II基因型为主(50%)，重症患者以DD基因型为主(63.3%)。ACE II基因型对严重COVID-19具有保护作用[OR和95% CI: .323(.112-.929)]。死亡的9例患者(8.9%)均为重症患者。结论:新冠肺炎感染的临床严重程度可能与ACE I/D多态性有关。局限性:样本量小，单中心。利益冲突:无。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Saudi Medicine 医学-医学：内科

CiteScore

2.80

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： The Annals of Saudi Medicine (ASM) is published bimonthly by King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. We publish scientific reports of clinical interest in English. All submissions are subject to peer review by the editorial board and by reviewers in appropriate specialties. The journal will consider for publication manuscripts from any part of the world, but particularly reports that would be of interest to readers in the Middle East or other parts of Asia and Africa. Please go to the Author Resource Center for additional information.